Physician profile
Peter D Hart
NPI 1043237050
$2,216.04
in general payments reported to CMS, 2019-2025
12 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $172 · 2021: $179 · 2022: $392 · 2023: $490 · 2024: $380 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $615.54 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $451.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $280.47 | 2020-2024 | Xarelto |
| Aurinia Pharma U.S., INC. | $254.28 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $201.82 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $157.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $56.97 | 2023-2025 | |
| Omeros Corporation | $55.50 | 2019 | |
| Merck Sharp & Dohme LLC | $48.18 | 2023 | Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $42.08 | 2022 | |
| Abbott Laboratories | $28.85 | 2025 | Cardiomems |
| Ani Pharmaceuticals, INC. | $22.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.